2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1437 Kit D816V drives EGR1-dependent LIF upregulation to promote proliferation through the JAK2-STAT3-CCL2 axis in systemic mastocytosis

Rui Jiang, Zhibo Zhang2, Wenqiang Qu3, Meiyu Chen4, Qing Yuan Wang5, Linlin Wang6, Qian Wang7, Jia Yin, MD, PhD8, Suning Chen9, Depei Wu Sr, MD10, Zhao Zeng, PhD11
1 First Affiliated Hospital of Soochow University, Suzhou, China
2 First Affiliated Hospital of Soochow University, Suzhou, China
3 First Affiliated Hospital of Soochow University, Suzhou, China
4 Changzhou No.2 People's Hospital, Changzhou, China
5 First Affiliated Hospital of Soochow University, Suzhou, China
6 Yancheng No.1 People's Hospital, Yancheng, China
7 First Affiliated Hospital of Soochow University, Suzhou, China
8 First Affiliated Hospital of Soochow University, Suzhou, China
9 First Affiliated Hospital of Soochow University, Suzhou, China
10 First Affiliated Hospital of Soochow University, Suzhou, China
11 First Affiliated Hospital of Soochow University, Suzhou, China

Background: Systemic mastocytosis (SM), especially advanced SM (AdvSM), carries a poor prognosis despite available KIT inhibitors (eg. avapritinib, midostaurin). The role of leukemia inhibitory factor (LIF), a pleiotropic IL-6 family cytokine, remains undefined in SM. We investigated LIF dysregulation in SM, elucidated its mechanistic link to oncogenic KIT D816V, and evaluated the therapeutic efficacy of LIF/LIFR blockade as monotherapy and in combination with KIT inhibitors.
Methods: We queried public transcriptomic datasets (GSE103223, GSE216446, GSE222830) and performed RNA-sequencing on bone marrow (BM). Serum LIF was quantified by ELISA in an independent cohort (including healthy controls and SM). CRISPR-Cas9 generated LIF knockout (KO) in KIT D816V-transduced HMC-1.1 cells. Proliferation, colony formation, and apoptosis were assessed in vitro, alongside cell-derived xenograft (CDX) models in vivo. Mechanistic studies integrated RNA-seq, CUT&Tag, and immunoblotting. Pharmacologic LIF/LIFR inhibition employed EC359.
Results: LIF mRNA and protein were significantly elevated in SM patients versus controls and other myeloid neoplasms (p<0.01). KIT D816V ectopic expression drove LIF upregulation, while avapritinib and midostaurin suppressed LIF expression in KIT D816V-transduced HMC-1.1 and P815 cells. LIF KO profoundly impaired proliferation and colony formation across serial passages. In CDX models, LIF KO reduced tumor burden, decreased peripheral blood disease, and extended survival (p=0.0025). Mechanistically, integrative CUT&Tag and transcriptomic analyses identified EGR1 as a direct transcriptional activator of LIF downstream of KIT D816V. LIF KO abrogated JAK2/STAT3 signaling, and STAT3 inhibition recapitulated the anti-proliferative phenotype. CCL2 emerged as a critical downstream effector, markedly downregulated upon LIF KO (log2FC= -0.741, adj. p<0.001), and CCL2 overexpression rescued the proliferative defect, validating the KIT-D816V-EGR1-LIF-JAK2/STAT3-CCL2 axis. Pharmacologic LIF/LIFR blockade with EC359 inhibited HMC-1.1 growth (IC50=0.48 µM), induced apoptosis, and suppressed CDX tumor growth. Notably, EC359 synergized with avapritinib and midostaurin (Loewe synergy scores 12.08 and 5.36, respectively), yielding significantly enhanced apoptosis over single agents.
Conclusions: We identify LIF as a novel, KIT D816V-driven oncogenic cytokine in SM that promotes proliferation via the JAK2/STAT3-CCL2 cascade. Targeting LIF/LIFR with EC359 demonstrates potent preclinical efficacy and marked synergy with standard-of-care KIT inhibitors, providing a strong translational rationale for clinical trials in SM.

Zhao Zeng, PhD: No relevant conflicts of interest to declare.